Pancreatic AdenocarcinomaCancerDrugProcedurePhase 2
What this study is
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
What's being tested
- Nivolumab
Intervention · DRUG
Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
- Irreversible Electroporation
Intervention · PROCEDURE
Non-thermal ablation of tumor
Study details
- Sponsor
- University of Louisville
- Conditions
- Pancreatic Adenocarcinoma
- Enrolling
- 10 people
- Starts
- 2017-08-14
- Est. completion
- 2029-04-01
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- ≥ 18 years if age
- Diagnosed with stage III pancreatic cancer
- Tumor is measurable
- Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)
- Willing and able to comply with the protocol requirements
- Able to comprehend and have signed the informed consent to participate
You can't join if
- Participating in another clinical trial for the treatment of cancer at time of screening
- Are pregnant or currently breast feeding
- Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
- Have non-removable implants with metal parts within 1 cm of the target lesion
- Had a myocardial infarction within 3 months prior to enrollment
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Louisville
Louisville, Kentucky, United States
Recruiting
Study team
Sponsor
University of Louisville
Study ID 16.1190
Principal investigator
Robert Martin, MD, PhD
University of Louisville
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.